It has been noted that CYP2E1 has played a role in oxidative stress in hepatitis C (Smirnova et al., 2016), and increased CYP2E1 levels have been associated with higher risk of adverse events, such as hepatotoxicity, especially in potential COVID-19 patients with obesity and metabolic (dysfunction)-associated fatty liver disease (MAFLD) as a comorbidity (Ferron et al., 2020). Here, CYP2E1 is linked to obesity disorder.